Delivery Order SPE2DB22D1017-SPE2DB24FF7MG

Award Date 5/9/24
Potential Completion Date 5/10/24
Potential Value $6.2K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,612.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a pharmaceutical product used for diabetes management. The contract is a Firm Fixed Price Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
This federal contract award, valued at $10,654.83, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used to treat diabetes. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the...
This federal contract award, valued at $10,449.36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of December 7, 2023. This award is associated with a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,967.89 firm fixed-price delivery order is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a medication used for diabetes management. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical. This single-award IDC serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $20,898.72 delivery order contract is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication used for diabetes management. The contract is a firm fixed-price delivery order with a performance period ending on December 7, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and...
This federal contract award was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The firm-fixed-price delivery order is valued at $12,307.75 and covers the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml medication. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves...
This federal contract award, valued at $3,069.72, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of Ozempic, a prescription medication used to treat type 2 diabetes, with an ultimate completion date of January 30, 2024. The contract is a delivery order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with...
This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a specialty pharmaceutical product. The fixed-price delivery order, valued at $1,510.48, has a period of performance that runs through January 12, 2024. The contract is part of a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $1,846.86, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a pharmaceutical product, to support military healthcare programs. The contract is a delivery order under an Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Cencora, Inc., which has a total potential value of up to $999,999,999.00 and...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a specialty medication used for diabetes management. The contract has a ceiling value of $11,627.83 and a completion date of January 24, 2024. This appears to be a delivery order against a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical,...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB24FF7MG
    Delivery Order

This federal contract award, valued at $6,224.04, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication, with a performance period ending on May 10, 2024.

The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. The contract was awarded through full and open competition without any set-aside designation.

Generated 5/16/25, 12:31 PM